Neoadjuvant treatments for triple-negative breast cancer (TNBC)

Annals of Oncology

Volumn 23, Issue SUPPL. 6, 2012, Pages

  von Minckwitz, G ^a   Martin, M ^b  

^a GBG Forschungs GmbH   (Germany)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Chemotherapy; Neoadjuvant; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; EPOTHILONE DERIVATIVE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; INIPARIB; IXABEPILONE; METHOTREXATE; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG RESPONSE; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT;

EID: 84867128805     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds193     Document Type: Article

References (48)

1. Cleere DW. Triple-negative breast cancer: a clinical update. Community Oncol 2011; 7: 203-211.
2. Clarke M, Coates AS, Darby SC et al. Adjuvant chemotherapy in oestrogenreceptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008; 371: 29-40.
3. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295: 1658-1667.
4. Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90: 1205-1211.
5. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
6. von Minckwitz G, Untch M, Nuesch E et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145-156.
7. Mehta RS. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. J Clin Oncol 2008; 26: 3286-3288.
8. Koya S, Li Y, McDaniel SA et al. Safety and effectiveness of dose sense neoadjuvant chemotherapy in patients with stage II/III breast cancer. J Clin Oncol 2009; 27(suppl): Abstr e11586.
9. Sikov WM, Dizon DS, Strenger R et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 2009; 27: 4693-4700.
10. von Minckwitz G, Loibl S, Maish A et al. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. Breast 2011; 20(Suppl. 3): S142-S145.
11. Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
12. Kennedy CR, Gao F, Margenthaler JA. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer. J Surg Res 2010; 163: 52-57.
13. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
14. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
15. Huober J, von Minckwitz G, Denkert C et al. Effect of neoadjuvant anthracyclinetaxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124: 133-140.
16. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast 2010; 19: 312-321.
17. Di Leo A, Isola J, Piette F et al A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Proceedings of the 31st CTRC-AACR San Antonio Breast Cancer Symposium, December 10- 14, 2008, San Antonio, TX; AACR Philadelphia, PA: Abstr 705.
18. Sikov WM, Perou CM, Golsham M et al. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. J Clin Oncol 2010; 28: 15s: Abstr TPS110.
19. Martin M, Romero A, Lopez Garcia-Asenjo et al. Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC). J Clin Oncol 2010; 28: 15s: Abstr 502.
20. Martin M, Romero A, Cheang MC et al. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 2011; 128: 127-136.
21. Smith LA, Cornelius VR, Plummer CJ et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010; 10: 337.
22. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010; 12: S3.
23. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
24. Rottenberg S, Nygren AO, Pajic M et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007; 104: 12117-12122.
25. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
26. Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
27. Gronwald J, Byrski T, Huzarski T et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol 2009; 27: 15s: Abstr 502.
28. German Breast Group: GepartoSixto study: http://www.germanbreastgroup.de (6 January 2012, date last accessed).
29. Buchholz TA, Hunt KK, Whitman GJ et al. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003; 98: 1150-1160.
30. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
31. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
32. Maur M, Guarneri V, Frassoldati A et al. Primary systemic therapy in operable breast cancer: clinical data and biological fall-out. Ann Oncol 2006; 17(Suppl. 5): v158-v164.
33. Gerber B, Eidtman H, Rezai M et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: seconday endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol 2011; 29(suppl): Abstr 1006.
34. Bear HD, Tang G, Rastogi M et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011; 29(suppl): Abstr LBA1005.
35. von Minckwitz G, Eidtman H, Rezai M et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Proceedings of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX; AACR Philadelphia, PA: Abstr S4-6.
36. D'Agostino RB. Changing end points in breast-cancer drug approval - the Avastin story. N Eng J Med 2011; 365: e2.
37. http://clinicaltrials.gov (6 January 2012, date last accessed).
38. Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008; 13: 1207-1223.
39. Baselga J, Zambetti M, Llombart-Cussac A et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009; 27: 526-534.
40. Kim D, Jung W, Koo JS. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci 2011; 26: 352-359.
41. Dent RA, Lindeman GJ, Clemons M et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010; 28: 15s: Abstr 1018.
42. Gelmon KA, Hirte HW, Robidoux A et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 2010; 28: 15s: Abstr 3002.
43. Llombart A, Lluch A, Villanueva C et al. SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). J Clin Oncol 2012; 30(Suppl): Abstr 1011.
44. von Minckwitz G, Muller BM, Loibl S et al. Cytoplasmic poly(ADP-ribose)polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29: 2150-2157.
45. Chen XS, Nie XQ, Chen CM et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 2010; 21: 961-967.
46. Kern P, Kimmig R, Kolberg HC et al. Neoadjuvant carboplatin and docetaxel for triple-negative breast cancer. Proceedings of the American Society of Clinical Oncology Breast Cancer Symposium 2010: Abstr 279.
47. Roy V, Pockaj BA, Northfelt BW et al. N0338 phase ll trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage ll or lll breast cancer. J Clin Oncol 2008; 26(suppl): Abstr 563.
48. Chang HR, Glaspy J, Allison MA et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010; 116: 4227-4237.